Advertisement

2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study

KPd is well tolerated and highly active (≥PR 84%) with encouraging PFS (median 12.9 mo) in less pretreated, mostly LEN-refractory and PI-naive/sensitive RRMM in the era of increased use of extended LEN treatment. 

 ASCO

click me